Phase I crossover study of DNA-protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension

被引:2
|
作者
Becker, Andreas [1 ]
Krebs-Brown, Axel [1 ]
Vetter, Claudia [1 ]
Reuter, Tanja [1 ]
Rodriguez-Gutierrez, Almudena [2 ,3 ]
You, Xiaoli [4 ]
Lissy, Michael [5 ]
机构
[1] Healthcare Business Merck KGaA, Frankfurter Str 250,F135-003, D-64293 Darmstadt, Germany
[2] SLU, Merck, Madrid, Spain
[3] Merck KGaA, Darmstadt, Germany
[4] EMD Serono, Billerica, MA USA
[5] NUVISAN GmbH, Neu Ulm, Germany
来源
关键词
CRYO-EM STRUCTURE; PK; ATM;
D O I
10.1111/cts.13657
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Peposertib is an orally administered inhibitor of DNA-dependent protein kinase. We evaluated the effect of food on its pharmacokinetics, and examined the pharmacokinetics of an oral suspension (OS) of disintegrated tablets, in a phase I, open-label, crossover three-period study (NCT04702698). Twelve healthy volunteers were randomized to one of six treatment sequences. They received a single dose of peposertib 100 mg as film-coated tablets under fasted or fed conditions ("tablet fasted" or "tablet fed") or as an OS under fasted conditions ("OS fasted"), with washout between treatments. Using healthy volunteers was possible because, despite its mechanism of action being suppression of DNA repair, peposertib has shown no genotoxic effect in animals. A mild food effect was observed with peposertib tablets. Fed-to-fasted ratios were: area under the curve from time 0 to time t (AUC(0-t)), 123.81% (90% confidence interval [CI]: 108.04, 141.87%); AUC from zero to infinity (AUC(0-infinity)), 110.28% (90% CI 100.71, 120.77%); and maximum concentration (C-max) 104.47% (90% CI: 79.15, 137.90%). C-max was delayed under fed conditions (median time to maximum concentration [T-max] was 3.5 h [tablet fed] vs. 1 h [tablet fasted]). OS-to-tablet (fasted) ratios were: AUC(0-t), 124.83% (90% CI: 111.50%, 139.76%); AUC(0-infinity), 119.05% (90% CI: 104.47, 135.67%); and C-max 173.29% (90% CI: 135.78, 221.16%). Median T-max was 0.5 h (OS fasted) versus 1 h (tablet). All treatments were well-tolerated in healthy volunteers. Peposertib tablets can be taken with or without food; if combined with chemotherapy or radiotherapy, the delay in C-max must be considered to optimize the chemo- or radiosensitizing effect. The peposertib OS form represents an alternative route of administration in patients with specific cancers causing dysphagia. However, the OS form should be part of future dose optimization strategies in relevant settings.
引用
收藏
页码:2628 / 2639
页数:12
相关论文
共 50 条
  • [31] A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers
    Cantarini, MV
    Macpherson, MP
    Marshall, AL
    Robinson, AV
    Bailey, CJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (06) : 557 - 562
  • [32] A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers
    Mireille V. Cantarini
    Merran P. Macpherson
    Anna L. Marshall
    Anna V. Robinson
    Christopher J. Bailey
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 557 - 562
  • [33] FIRST-IN-HUMAN PHASE I STUDY OF ETC-206 AN ORAL MNK 1/2 KINASE INHIBITOR IN HEALTHY VOLUNTEERS.
    Teneggi, V.
    Novotny-Diermayr, V.
    Yasin, M.
    Yeo, P.
    Ethirajulu, K.
    Gan, S.
    Lee, L.
    Blanchard, S.
    Nellore, R.
    Umrani, D.
    Hill, J.
    Kassoum, N.
    Ong, S.
    Lim, W.
    Lu, Q.
    Yang, C.
    Matter, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S89 - S89
  • [34] Effect of food on the pharmacokinetics and safety profiles of a new PARP inhibitor fuzuloparib capsules in healthy volunteers
    Du, Pengfei
    Long, Yao
    Wang, Minhui
    Huang, Yunzhe
    Wang, Yaqin
    Chen, Xinyan
    Lin, Yuhong
    Wu, Jianbang
    Shen, Jie
    Jia, Yuanwei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (02) : 251 - 257
  • [35] Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers
    Shaik, M. Naveed
    LaBadie, Robert R.
    Rudin, Dan
    Levin, Wendy J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 411 - 418
  • [36] Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
    Shaik, Naveed
    Hee, Brian
    Wei, Hua
    LaBadie, Robert R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (03) : 463 - 472
  • [37] Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers
    M. Naveed Shaik
    Robert R. LaBadie
    Dan Rudin
    Wendy J. Levin
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 411 - 418
  • [38] Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
    Naveed Shaik
    Brian Hee
    Hua Wei
    Robert R. LaBadie
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 463 - 472
  • [39] Evaluation of the Effect of Food and Age on the Pharmacokinetics of Oral Netupitant and Palonosetron in Healthy Subjects: A Randomized, Open-Label, Crossover Phase 1 Study
    Calcagnile, Selma
    Lanzarotti, Corinna
    Gutacker, Michaela
    Jakob-Rodamer, Verena
    Kammerer, Klaus Peter
    Timmer, Wolfgang
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (05): : 377 - 386
  • [40] Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants
    Ji, Wei
    Jiang, Yu
    Wei, Yilin
    He, Kun
    Mu, Hongli
    Wen, Qing
    Zhang, Xiaoran
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (09): : 1046 - 1053